Pharma BD Deal Intelligence

Bristol-Myers Squibb Company / Ono Pharmaceutical Co., Ltd.

2014 · Co-Development · Complete

BMS and Ono expanded their long-running PD-1 collaboration to jointly develop and commercialize Opdivo, Yervoy and three early immunotherapies in Japan, South Korea and Taiwan—markets where Ono historically retained rights. Strategically pivotal as Opdivo received the world's first PD-1 approval in Japan that same month.

Key facts

• Announced Jul 23, 2014
• Closed Jul 23, 2014
• Deal type Co-Development
• Therapeutic area Multiple cancers across Asia-Pacific
• Indications Multiple cancers across Asia-Pacific
• Key assets Opdivo (nivolumab), Yervoy (ipilimumab) plus three early-stage immunotherapies
• Mechanism PD-1 and CTLA-4 immune checkpoint inhibition

← Browse all deals  ·  How we score deals